⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. Drive Therapeutics — Bispecific Aptamer Platform just got measured.
4/10 means Drive Therapeutics — Bispecific Aptamer Platform is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
Platform D28P001 Pipeline Team Investor Portal Contact Us Preclinical-Stage Biotherapeutics First-in-Class Bispecific Aptamer Targeting VEGF + IL‑8 Drive Therapeutics is developing D28P001, a dual-mechanism aptamer platform designed to treat diseases where angiogenesis and inflammation converge — starting with retinal disorders and expanding into endometriosis.
1
Structured Data
6
Content Structure
5
Entity Clarity
3
E-E-A-T Signals
5
Technical AEO
4
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
Tech buyers are the most research-intensive shoppers on the internet.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for Drive Therapeutics — Bispecific Aptamer Platform.
Scored by Engagemii on June 28, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/drivetherapeutics
Cite this score: Engagemii (2026). "AEO Score for Drive Therapeutics — Bispecific Aptamer Platform." Retrieved from https://engagemii.com/aeo/brands/drivetherapeutics
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform